Ulrike Gnad-Vogt

1.8k total citations · 1 hit paper
28 papers, 1.0k citations indexed

About

Ulrike Gnad-Vogt is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ulrike Gnad-Vogt has authored 28 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Ulrike Gnad-Vogt's work include Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and RNA Interference and Gene Delivery (7 papers). Ulrike Gnad-Vogt is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and RNA Interference and Gene Delivery (7 papers). Ulrike Gnad-Vogt collaborates with scholars based in Germany, Switzerland and France. Ulrike Gnad-Vogt's co-authors include Mariola Fotin‐Mleczek, Sven D. Koch, Ingmar Hoerr, Henoch S. Hong, Linus Backert, Greg Finak, Martin Alberer, Keyvan Tadjalli Mehr, Raphaël Gottardo and Ralf Clemens and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of Hepatology.

In The Last Decade

Ulrike Gnad-Vogt

27 papers receiving 992 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

2017 373 citations Martin Alberer, Ulrike Gnad-Vogt et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulrike Gnad-Vogt Germany	11	649	496	279	257	144	28	1.0k
Jochen Probst Germany	14	1.2k 1.8×	893 1.8×	263 0.9×	212 0.8×	333 2.3×	18	1.5k
Nitya Nair United States	15	340 0.5×	680 1.4×	379 1.4×	261 1.0×	82 0.6×	28	1.2k
Steven Tuyishime United States	7	662 1.0×	247 0.5×	262 0.9×	85 0.3×	210 1.5×	8	923
Jonathan K. Fallon United States	11	468 0.7×	407 0.8×	160 0.6×	232 0.9×	37 0.3×	13	989
Elena Cherkasova United States	13	361 0.6×	216 0.4×	339 1.2×	196 0.8×	88 0.6×	30	950
Gustaf Lindgren Sweden	9	344 0.5×	438 0.9×	239 0.9×	84 0.3×	63 0.4×	14	761
Mark H. Fogg United States	14	270 0.4×	291 0.6×	135 0.5×	277 1.1×	54 0.4×	26	767
R M Conry United States	11	476 0.7×	357 0.7×	128 0.5×	129 0.5×	226 1.6×	11	722
Jeff Fairman United States	19	368 0.6×	208 0.4×	182 0.7×	72 0.3×	101 0.7×	44	914
Marta Łuksza United States	7	328 0.5×	319 0.6×	128 0.5×	318 1.2×	160 1.1×	8	862

Countries citing papers authored by Ulrike Gnad-Vogt

Since Specialization

Citations

This map shows the geographic impact of Ulrike Gnad-Vogt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Gnad-Vogt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Gnad-Vogt more than expected).

Fields of papers citing papers by Ulrike Gnad-Vogt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Gnad-Vogt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Gnad-Vogt. The network helps show where Ulrike Gnad-Vogt may publish in the future.

Co-authorship network of co-authors of Ulrike Gnad-Vogt

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Gnad-Vogt. A scholar is included among the top collaborators of Ulrike Gnad-Vogt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Gnad-Vogt. Ulrike Gnad-Vogt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tabatabai, Ghazaleh, Pierre Frères, Peter Hau, et al.. (2025). O-09.03 Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma. Oral Presentations. A3–A3. 1 indexed citations

Frères, Pierre, Martin Glas, Martin J. van den Bent, et al.. (2024). 440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase. Annals of Oncology. 35. S406–S406. 2 indexed citations

Eigentler, Thomas, Lucie Heinzerling, Juergen Krauss, et al.. (2021). 1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008. Annals of Oncology. 32. S853–S853. 3 indexed citations

Doener, Fatma, Henoch S. Hong, Ingo Meyer, et al.. (2019). RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. Vaccine. 37(13). 1819–1826. 37 indexed citations

Terheyden, Patrick, Carsten Weishaupt, Lucie Heinzerling, et al.. (2018). Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors. Annals of Oncology. 29. viii466–viii466. 4 indexed citations

Accolla, Roberto S., Yuling Ma, Regina Heidenreich, et al.. (2017). Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC. Journal of Hepatology. 66(1). S445–S446. 1 indexed citations

Stenzl, Arnulf, Isabel Syndikus, Tomasz Sarosiek, et al.. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v408–v409. 32 indexed citations

Alberer, Martin, Ulrike Gnad-Vogt, Henoch S. Hong, et al.. (2017). Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet. 390(10101). 1511–1520. 373 indexed citations breakdown →

Hong, Henoch S., Sven D. Koch, Birgit Scheel, et al.. (2016). Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy. OncoImmunology. 5(12). e1249560–e1249560. 18 indexed citations

10.

Groß, Stefanie, Volker Lennerz, Elisa Gallerani, et al.. (2015). Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer Immunology Research. 4(1). 18–25. 18 indexed citations

11.

Kübler, Hubert, Birgit Scheel, Ulrike Gnad-Vogt, et al.. (2015). Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. Journal for ImmunoTherapy of Cancer. 3(1). 26–26. 211 indexed citations

12.

Heidenreich, Regina, Keyvan Tadjalli Mehr, Sven D. Koch, et al.. (2015). RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P163–P163. 2 indexed citations

13.

Koch, Sven D., Henoch S. Hong, Susan Feyerabend, et al.. (2014). A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. Journal for ImmunoTherapy of Cancer. 2(Suppl 3). P85–P85. 5 indexed citations

14.

Sebastian, Martin, Alexandros Papachristofilou, Christian Weiß, et al.. (2014). Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 14(1). 748–748. 113 indexed citations

15.

Lennerz, Volker, Stefanie Groß, Elisa Gallerani, et al.. (2014). Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy. 63(4). 381–394. 93 indexed citations

16.

Kallen, Karl‐Josef, Ulrike Gnad-Vogt, Birgit Scheel, Gerd Rippin, & Arnulf Stenzl. (2013). A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses. Journal for ImmunoTherapy of Cancer. 1(S1). 6 indexed citations

17.

Laurent, Julien, Cédric Touvrey, Silke Gillessen, et al.. (2013). T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine. 11(1). 5–5. 26 indexed citations

18.

Gillessen, Silke, Ulrike Gnad-Vogt, Elisa Gallerani, et al.. (2012). A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. European Journal of Cancer. 49(1). 35–44. 45 indexed citations

19.

Ernst, Thomas, Kirsten Merx, Ulrike Gnad-Vogt, et al.. (2007). Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. British Journal of Cancer. 97(11). 1475–1479. 1 indexed citations

20.

Hofheinz, Ralf‐Dieter, Ulrike Gnad-Vogt, Axel Wein, et al.. (2004). Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drugs. 16(1). 39–45. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact